Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Agamree is a prescription corticosteroid containing vamorolone. It is approved for Duchenne muscular dystrophy (DMD) in patients age 2 and older. Agamree is supplied as a 40 mg/mL oral suspension. Treatment is taken once daily, preferably with a meal. The prescribed amount is based on body weight, liver function, tolerability, and use of certain interacting medicines.
read more about agamree ...Vamorolone acts through the glucocorticoid receptor and produces anti-inflammatory and immunosuppressive effects. The exact mechanism responsible for its clinical effect in Duchenne muscular dystrophy is not known. Corticosteroid activity can also suppress the hypothalamic-pituitary-adrenal axis, which is one reason treatment lasting longer than one week is tapered rather than stopped abruptly.
Agamree is approved for Duchenne muscular dystrophy in patients age 2 and older. Duchenne muscular dystrophy is a genetic muscle disorder marked by progressive muscle weakness. Agamree is a corticosteroid treatment used as part of medical management for the disease. The labeled indication applies to pediatric and adult patients who meet the age requirement.
Agamree is taken by mouth once daily, preferably with a meal. The recommended dose is 6 mg per kg of body weight, capped at 300 mg daily for patients weighing more than 50 kg. Lower doses are used for mild to moderate liver impairment or with strong CYP3A4 inhibitors. The bottle is shaken well before each measured dose.
Agamree can suppress adrenal function and raise infection risk. Other concerns include increased blood sugar, elevated blood pressure, sodium or potassium changes, gastrointestinal perforation, behavioral or mood changes, decreased bone mineral density, cataracts, glaucoma, altered growth in children, blood clots, and anaphylaxis. Live vaccines are avoided during treatment. Abrupt withdrawal after longer treatment can trigger adrenal insufficiency.
Yes. Agamree contains vamorolone, a corticosteroid that acts through glucocorticoid receptors and has anti-inflammatory and immunosuppressive activity.
Agamree is approved for Duchenne muscular dystrophy in patients age 2 and older.
Agamree is taken once daily by mouth, preferably with a meal. The dose is calculated from body weight and other clinical factors.
Stopping after more than one week of treatment requires gradual dose reduction. Abrupt withdrawal can raise the risk of adrenal insufficiency.
AGAMREE (vamorolone) Oral Suspension Prescribing Information. https://agamree.com/wp-content/uploads/2024/10/AGAMREE-PI-06-2024-1.pdf. Date Accessed September 11, 2026.
AGAMREE (vamorolone) Oral Suspension Instructions for Use. https://agamree.com/wp-content/uploads/2024/10/AGAMREE-IFU-06-2024.pdf. Date Accessed September 11, 2026.
DailyMed - AGAMREE (vamorolone) Oral Suspension. https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=fb376f09-cf9c-42b5-b4dd-02d5bcd73211. Date Accessed September 11, 2026.
Drug Trials Snapshots: AGAMREE. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-agamree. Date Accessed September 11, 2026.
Search Orphan Drug Designations and Approvals - Vamorolone. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=343111. Date Accessed September 11, 2026.